ClinicalTrials.gov
public full text
Public Domain
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
We propose to conduct a phase 2 study to assess whether the addition of acitretin to vemurafenib therapy is able to decrease the rate of cutaneous squamous cell carcinoma (cSCC) development, a known side effect of vemurafenib therapy, in patients with advanced melanoma. Further, we seek a preliminary assessment as to whether the addition of acitretin to vemurafenib enhances the clinical efficacy of this anti-melanoma agent.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Evaluation of Side Effects of Mitotane#1086182
- Gut microbial markers of immunotherapy response in melanoma: a cross-cohort analysis including the first Russian dataset.#288690
- Baseline C-reactive protein independently predicts treatment response and survival in metastatic melanoma patients receiving first-line immune checkpoint inhibitors#1028844
- Preventive Approach Using Venlafaxine#966344
- Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics#1008216
Record · ID 878483
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive